#Hong Kong #siRNA #Ribo Life Science

Ribo Life Science Achieves Significant Market Listing

Ribo Life Science Co., Ltd. (ticker: 06938.HK) has reached a notable milestone by successfully listing on the main board of the Hong Kong Stock Exchange, positioning the company at the forefront of the small interfering RNA (siRNA) therapeutic sector. This achievement marks a pivotal moment in the capitalization of Chinese biopharmaceutical enterprises, injecting renewed momentum into the industry.

The company successfully issued a total of 31,610,400 shares at an offering price of HKD 57.97 per share, raising over HKD 1.8 billion in gross proceeds. This public offering (HKPO) witnessed overwhelming demand, being oversubscribed more than 100 times, while the international placement alone was oversubscribed by 16.7 times. Such figures reflect robust global investor confidence in the potential of the siRNA market and Ribo's capabilities within it. The proceeds from this listing will provide a solid financial foundation for the company's core business expansion. Furthermore, the offering attracted a dozen prominent investors, including Arc Avenue, Ivy Rock, Springs Capital, and others, showcasing the trust leading institutions place in Ribo's long-term prospects.

Zicai Liang, the Founder, President, and CEO of Ribo, expressed his gratitude towards global investors, stating, "Listing on the Hong Kong Stock Exchange represents a significant milestone in Ribo's journey. We aim to leverage international financial markets to expedite global clinical development and commercialization of siRNA-based therapeutic products, reinforce our technologies, and deliver innovative treatments to patients worldwide while generating sustainable value for our shareholders."

The funds raised will be allocated across four key areas:
1. Development of global multicenter clinical trials for flagship products.
2. Preclinical and clinical progression of the product pipeline.
3. Enhancement and refinement of siRNA delivery technology and associated platforms.
4. Strengthening operational capital and setting aside funds for ongoing corporate needs.

Ribo Life Science has established a fully integrated research and development platform, backed by independent intellectual property rights. Their innovative RiboGalSTARTM delivery technology targeting the liver has been instrumental in the successful development of several products currently in Phase II clinical trials. The company has set up R&D centers in Suzhou, Beijing, and Gothenburg, Sweden, creating a global R&D network capable of supporting end-to-end drug development from discovery through to global clinical trials.

The listing was jointly sponsored by China International Capital Corporation and Citigroup, who provided professional support crucial to Ribo's success on the capital markets.

About Ribo Life Science

Suzhou Ribo Life Science Co., Ltd. (06938.HK) is an international biopharmaceutical company dedicated to the development and commercialization of therapeutic siRNA products. Through exclusive and innovative siRNA technology platforms, Ribo has built a rich and differentiated product portfolio targeting significant diseases, including cardiovascular, metabolic, liver, and kidney diseases. Ribo is committed to providing revolutionary therapeutic solutions to patients worldwide through continuous innovation.

For more information, visit www.ribolia.com.